We are live on
!
Find out more
Primecap Management Portfolio holdings
AUM
$127B
1-Year Est. Return
44.11%
This Fund
S&P 500
This Quarter
Est. Return
+4.87%
1 Year Est. Return
+44.11%
3 Year Est. Return
+121.64%
5 Year Est. Return
+154.22%
10 Year Est. Return
+724.54%
AUM
$102B
AUM Growth
+$1.43B
(+1.4%)
Cap. Flow
-$1.09B
Cap. Flow
% of AUM
-1.07%
Top 10 Holdings %
Top 10 Hldgs %
32.54%
Holding
287
New
14
Increased
80
Reduced
134
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qiagen
QGEN
|
+$518M |
| 2 |
AstraZeneca
AZN
|
+$246M |
| 3 |
Alkermes
ALKS
|
+$172M |
| 4 |
Whirlpool
WHR
|
+$94.4M |
| 5 |
Eli Lilly
LLY
|
+$78.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
QGENF
QIAGEN NV
QGENF
|
+$534M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$265M |
| 3 |
Amgen
AMGN
|
+$235M |
| 4 |
NVIDIA
NVDA
|
+$233M |
| 5 |
Microsoft
MSFT
|
+$177M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.81% |
| 2 | Healthcare | 22.95% |
| 3 | Industrials | 16.75% |
| 4 | Consumer Discretionary | 9.17% |
| 5 | Financials | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$29.8B
| $4.42B | 4.35% |
15,584,387
-109,518
| -0.7% | -$32.5M |
|
|
2
Eli Lilly
LLY
$1.07T
| $4.23B | 4.16% |
57,501,098
+1,052,050
| +2% | +$78.3M |
|
|
3
Amgen
AMGN
$204B
| $3.66B | 3.6% |
24,999,391
-1,561,160
| -6% | -$235M |
|
4
Southwest Airlines
LUV
$21.8B
| $3.61B | 3.55% |
72,467,912
+26,850
| +0% | +$1.2M |
|
5
Texas Instruments
TXN
$257B
| $3.35B | 3.29% |
45,857,124
-1,436,152
| -3% | -$102M |
|
|
6
Microsoft
MSFT
$2.83T
| $3.33B | 3.28% |
53,576,304
-2,942,870
| -5% | -$177M |
|
7
FedEx
FDX
$74.8B
| $2.94B | 2.9% |
15,805,070
-22,000
| -0.1% | -$4.04M |
|
8
Adobe
ADBE
$86.8B
| $2.86B | 2.82% |
27,819,717
-264,007
| -0.9% | -$27.9M |
|
|
9
NVIDIA
NVDA
$5.04T
| $2.4B | 2.36% |
898,647,200
-111,575,000
| -11% | -$233M |
|
10
American Airlines Group
AAL
$9.23B
| $2.11B | 2.08% |
45,221,791
+926,565
| +2% | +$40.3M |
|
11
JPMorgan Chase
JPM
$931B
| $2.03B | 2% |
23,550,782
+87,475
| +0.4% | +$6.67M |
|
12
Alphabet (Google) Class A
GOOGL
$3.92T
| $1.93B | 1.9% |
48,683,660
-114,100
| -0.2% | -$4.56M |
|
|
13
Alphabet (Google) Class C
GOOG
$3.92T
| $1.87B | 1.84% |
48,531,240
+264,340
| +0.5% | +$10.3M |
|
|
SCHW
14
Charles Schwab
SCHW
$177B
| $1.79B | 1.76% |
45,240,000
-7,417,350
| -14% | -$265M |
|
15
Novartis
NVS
$296B
| $1.55B | 1.52% |
23,711,460
+769,365
| +3% | +$49.9M |
|
16
NetApp
NTAP
$32.7B
| $1.47B | 1.45% |
41,682,076
-112,275
| -0.3% | -$3.93M |
|
17
United Airlines
UAL
$37.9B
| $1.44B | 1.41% |
19,727,254
-115,397
| -0.6% | -$7.35M |
|
18
Alibaba
BABA
$270B
| $1.37B | 1.34% |
15,556,605
+177,700
| +1% | +$17.1M |
|
19
Micron Technology
MU
$1.06T
| $1.36B | 1.34% |
62,122,100
-11,000
| -0% | -$207K |
|
20
Hewlett Packard
HPE
$63.9B
| $1.3B | 1.28% |
96,356,620
-100,664
| -0.1% | -$1.34M |
|
21
Sony
SONY
$123B
| $1.24B | 1.22% |
221,415,250
-403,000
| -0.2% | -$2.45M |
|
22
CarMax
KMX
$8.36B
| $1.19B | 1.17% |
18,501,035
-298,715
| -2% | -$16.8M |
|
|
MON
23
DELISTED
Monsanto Co
MON
| $1.17B | 1.15% |
11,152,737
-20,096
| -0.2% | -$2.06M |
|
24
Intel
INTC
$491B
| $1.15B | 1.13% |
31,785,569
+353,425
| +1% | +$12.7M |
|
25
Carnival Corporation Ltd
CCL
$35.9B
| $1.13B | 1.11% |
21,715,980
-44,225
| -0.2% | -$2.21M |
|
Similar funds
Primecap Management's Q4 2016 Portfolio in Review
As of Q4 2016, Primecap Management held 287 positions worth $102B, up 1.4% from $100B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Primecap Management's Q4 2016 filing shows 14 new, 80 increased, 134 reduced and 11 closed positions. Its largest new stake was Qiagen: 17,384,319 shares worth $536M. The largest sale was QIAGEN NV, an estimated $534M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 30% a quarter earlier, followed by Healthcare and Industrials.
- Primecap Management's largest Q4 2016 buy was Qiagen: 17,384,319 shares worth $536M.
- Primecap Management added most to AstraZeneca in Q4 2016, an estimated $246M increase.
- Primecap Management's biggest Q4 2016 reduction was Charles Schwab, cutting an estimated $265M.
- Primecap Management fully exited QIAGEN NV in Q4 2016, selling an estimated $534M.
- Primecap Management's ten largest holdings make up 33% of its $102B portfolio in Q4 2016.
- Primecap Management opened 14 new positions and closed 11 in Q4 2016.
- Primecap Management's portfolio value rose 1.4% quarter-over-quarter to $102B.
Based on Primecap Management's 13F filing for Q4 2016, filed 13 Feb 2017.